Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | USP2 | O75604 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.53 |
| ▸ | GAA | P10253 | 6/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | HPGD | P15428 | 4/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | MAP2 | P11137 | 1/20 | 0.53 |
| ▸ | PPARG | P37231 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.53 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4592690 | 0.90 | ALDH1A1 (0.53) | MAPTLMNAUSP2TP53TSHR | |
| SCHEMBL4592062 | 0.88 | KDM4E (0.49) | MAPTLMNAUSP2TP53TSHR | |
| SCHEMBL4599752 | 0.88 | GPR35 (0.52) | MAPTLMNAUSP2TP53TSHR | |
| SCHEMBL5161760 | 0.88 | ALDH1A1 (0.60) | MAPTLMNAUSP2TP53TSHR | |
| SCHEMBL4599514 | 0.88 | MAPT (0.51) | MAPTLMNAUSP2TP53TSHR | |
| SCHEMBL4591604 | 0.88 | KDM4E (0.54) | MAPTLMNAUSP2TP53TSHR | |
| SCHEMBL9438067 | 0.87 | KDM4E (0.53) | MAPTLMNAUSP2TSHRKDM4E | |
| SCHEMBL4900969 | 0.87 | MAP2 (0.70) | MAPTLMNAUSP2TP53TSHR | |
| SCHEMBL5159252 | 0.86 | KDM4E (0.63) | MAPTLMNAUSP2TP53TSHR | |
| SCHEMBL4591856 | 0.85 | GPR35 (0.55) | MAPTLMNAUSP2TP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080317857-A1 | V-Atpase Inhibitors of Use in the Treatment of Septic Shock | BRANE DISCOVERY S.R.L. (IT) | 2008-12-25 | — | — | US | disclosed |
| US-20080317857-A1 | V-Atpase Inhibitors of Use in the Treatment of Septic Shock | BRANE DISCOVERY S.R.L. (IT) | 2008-12-25 | — | — | US | disclosed |
| US-20080226718-A1 | Indole and Azaindole Derivatives For the Treatment of Inflammatory and Autoimmune Diseases | BRANE DISCOVERY S.R.L (IT) | 2008-09-18 | — | — | US | disclosed |
| US-20080226718-A1 | Indole and Azaindole Derivatives For the Treatment of Inflammatory and Autoimmune Diseases | BRANE DISCOVERY S.R.L (IT) | 2008-09-18 | — | — | US | disclosed |
| US-20070248672-A1 | Indole and Azaindole Derivatives with Antitumor Action | NIKEM RESEARCH S.R.L. (IT) | 2007-10-25 | — | — | US | disclosed |
| US-20070248672-A1 | Indole and Azaindole Derivatives with Antitumor Action | NIKEM RESEARCH S.R.L. (IT) | 2007-10-25 | — | — | US | disclosed |
| US-20070248672-A1 | Indole and Azaindole Derivatives with Antitumor Action | NIKEM RESEARCH S.R.L. (IT) | 2007-10-25 | — | — | US | disclosed |
| EP-1750687-A2 | INDOLE AND AZAINDOLE DERIVATIVES WITH ANTITUMOR ACTION | NIKEM RESEARCH S.R.L. (IT) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005105213-A2 | INDOLE AND AZAINDOLE DERIVATIVES WITH ANTITUMOR ACTION | NIKEM RESEARCH S.R.L. (IT) | 2005-11-10 | — | — | WO | disclosed |
| US-5296499-A | Osteoporosis | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-03-22 | — | — | US | disclosed |
| EP-0449196-A2 | Indole derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1991-10-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070248672-A1 | Indole and Azaindole Derivatives with Antitumor Action | IDO1, IDO2, INMT | MAPT 4170/4885LMNA 2364/4885USP2 1683/4885 |
| US-20080226718-A1 | Indole and Azaindole Derivatives For the Treatment of Inflammatory and Autoimmune Diseases | IDO1, IDO2, INMT | MAPT 4048/4885LMNA 4749/4885USP2 2126/4885 |
| US-20080317857-A1 | V-Atpase Inhibitors of Use in the Treatment of Septic Shock | ATP6V1E1, ATP6V1H, ATP6V1G1 | MAPT 4121/4885LMNA 3864/4885USP2 2075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.